Scotiabank starts Viking Therapeutics at Outperform, sees attractive entry point
As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...
Why Viking Therapeutics Inc. (VKTX) Went Down on Monday
We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...
2 Stocks to Buy With Less Than $40
Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, ...
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...
Viking Therapeutics initiated with a Neutral at Citi
Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...
The Pharma Letter8d
Viking sails ahead with pivotal trial and billion dollar cash pile
San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...
Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials
Viking Therapeutics ( VKTX, Financials) reported its fourth-quarter and full-year 2024 financial results, highlighting ...
Has the Bubble Burst for Viking Therapeutics Stock?
The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. Many investors ...
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.
Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...